title: Non-invasive Respiratory Support and Severe Retinopathy of Prematurity.
abstract: The authors describe two premature infants who developed stage 3, zone I retinopathy of prematurity (ROP) with plus disease in both eyes, despite limited exposure to supra-ambient oxygen. Both infants received noninvasive respiratory support for several weeks. Both cases are notable because the ROP was more posterior and aggressive than is typical for the gestational ages or birth weights. These cases are insufficient to make definitive conclusions regarding the factors that cause ROP. Further investigation is required to determine if there is an association between the use of non-invasive respiratory support, even in the absence of supra-ambient oxygen, and severe ROP development. [J Pediatr Ophthalmol Strabismus. 2016;53:e47-e50.].
authors.forename: Rahul
authors.initials: R
authors.lastname: Raghu
authors.forename: Marilyn
authors.initials: M
authors.lastname: Fisher
authors.forename: Jennifer
authors.initials: J
authors.lastname: Cerone
authors.forename: Gerard
authors.initials: G
authors.lastname: Barry
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000068258:Bevacizumab / Q000627:therapeutic use; D001724:Birth Weight; D003131:Combined Modality Therapy; D045422:Continuous Positive Airway Pressure; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D019102:Infant, Very Low Birth Weight; D058449:Intravitreal Injections; D017075:Laser Coagulation; D008297:Male; D012121:Respiration, Artificial / Q000009:adverse effects*; D012127:Respiratory Distress Syndrome, Newborn / Q000628:therapy; D015861:Retinal Neovascularization / Q000145:classification / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D012171:Retinal Vessels / Q000473:pathology*; D012178:Retinopathy of Prematurity / Q000145:classification / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab